Eli Lilly's Mounjaro received FDA approval for reducing heart attack and stroke risks. This new indication expands its use beyond diabetes and weight management. The drug demonstrated an 8% greater reduction in cardiovascular events in a key study. Mounjaro's approval strengthens Eli Lilly's position in the GLP-1 medicine market. This development highlights the expanding medical potential of these widely used drugs.